LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Home・Stock List・Novartis AG

Novartis AG

Closed

116.68 0.16

Buy Sell

Overview

Share price change

24h

Current

Min

116.6

Max

116.9

Key metrics
By Trading Economics
Income	2.7B
Sales	344M 12B
P/E Sector Avg	23.59 103.001
EPS	1.31
Profit margin	22.178
EBITDA	4.7B

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+0.35 upside

Market Stats
By TradingEconomics
Market Cap	818M 247B
Previous open	116.52
Previous close	116.68

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

116.33 / 119.15 Support & Resistance

Novartis AG Chart

Related News

26 Aug 2024, 09:47 UTC

Acquisitions, Mergers, Takeovers

Novartis Confirms Offer for Diagnostic Arm From Siemens Healthineers

18 Jul 2024, 05:58 UTC

Earnings

Novartis Raises Profit Guidance as Key Drugs Boost Sales -- Update

18 Jul 2024, 05:42 UTC

Earnings

Novartis Raises Profit Guidance as Key Drugs Boost Sales

5 Jun 2024, 15:26 UTC

Acquisitions, Mergers, Takeovers

Cytokinetics CEO Says Board Would Have Backed Actionable Buyout

3 Sept 2024, 14:07 UTC

Market Talk

Novartis Has a Strong Drug Pipeline But Investor Optimism Is Yet to Grow -- Market Talk

19 Aug 2024, 13:36 UTC

Market Talk

Novartis Well on Track to Achieve Guidance -- Market Talk

14 Aug 2024, 09:02 UTC

Market Talk

Novartis Could Slash Guidance Amid Generic Heart-Drug Competition -- Market Talk

18 Jul 2024, 11:55 UTC

Earnings

Novartis Reports Near 40% Margin In Q2; Shares Slide -- IBD

18 Jul 2024, 09:40 UTC

Market Talk

Earnings

Novartis 2Q Results Seem Solid, Catalysts in Focus -- Market Talk

18 Jul 2024, 08:45 UTC

Market Talk

Earnings

Novartis Sales Beat Reflects Demand for New Drugs, Older Blockbusters Lag -- Market Talk

18 Jul 2024, 07:48 UTC

Market Talk

Novartis Prostate-Cancer Drug Pluvicto Sales Miss Raises Growth Questions -- Market Talk

18 Jul 2024, 07:01 UTC

Market Talk

Earnings

Novartis Profit Outlook Lift Reflects Blockbuster Drug Sales Boost, Operational Execution -- Market Talk

18 Jul 2024, 05:18 UTC

Earnings

Correct: Novartis 2Q Core Operating Profit $4.95B

18 Jul 2024, 05:03 UTC

Earnings

Novartis Had Seen Net Sales to Grow High-Single to Low Double-digit in 2024

18 Jul 2024, 05:03 UTC

Earnings

Novartis Net Sales Guidance in 2024 Unchanged

18 Jul 2024, 05:03 UTC

Earnings

Novartis Had Seen Core Operating Income to Grow Low Double-Digit to Mid-Teens in 2024

18 Jul 2024, 05:03 UTC

Earnings

Novartis Expects Core Operating Income to Grow Mid- to High Teens in 2024

18 Jul 2024, 05:02 UTC

Earnings

Novartis Raises 2024 Guidance

18 Jul 2024, 05:01 UTC

Earnings

Analysts Had 2Q Core Operating Profit at $4.67B

18 Jul 2024, 05:01 UTC

Earnings

Analysts Had 2Q Sales at $12.22B

18 Jul 2024, 05:01 UTC

Earnings

Novartis 2Q Sales $12.51B

18 Jul 2024, 05:01 UTC

Earnings

Novartis 2Q Core Operating Profit $12.51B

18 Jul 2024, 05:00 UTC

Earnings

Novartis AG 2Q EPS $1.60

18 Jul 2024, 05:00 UTC

Earnings

Novartis AG 2Q Adj EPS $1.97

18 Jul 2024, 05:00 UTC

Earnings

Novartis AG 2Q Net Pft $3.2B

20 Jun 2024, 06:35 UTC

Acquisitions, Mergers, Takeovers

MorphoSys Delisting From Frankfurt Stock Exchange, Nasdaq Expected to Take Place in 3Q

20 Jun 2024, 06:34 UTC

Acquisitions, Mergers, Takeovers

Novartis Delisting Offer Is In Line With Price of Acquisition Closed in May

20 Jun 2024, 06:33 UTC

Acquisitions, Mergers, Takeovers

Novartis to Offer EUR68 a Share in Cash to Minority MorphoSys Shareholders

20 Jun 2024, 06:32 UTC

Acquisitions, Mergers, Takeovers

Novartis Holds Around 91.04% of MorphoSys as of Thursday

20 Jun 2024, 06:31 UTC

Acquisitions, Mergers, Takeovers

Novartis to Start Squeeze-Out of MorphoSys' Minority Shareholders

Peer Comparison

Price change

Novartis AG Forecast

Price Target

By TipRanks

0.35% upside

12 Months Forecast

Average 116.9 USD 0.35%

High 125 USD

Low 97 USD

Based on 6 Wall Street analysts offering 12 month price targets forNovartis AG - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Novartis AG - Dist in the past 3 months.

Technical Score

By Trading Central

116.33 / 119.15Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Novartis AG

Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.